Glubia Combi Tablet 50/500 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hanol Bio Pharma Co., Ltd.
MFDS item code 201505858 · Approved 2015.08.20
This product's status changed to Approval withdrawn on 2023.12.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to aid in blood sugar control for patients with type 2 diabetes. It is administered to those who are starting diabetes medication therapy for the first time or for whom blood sugar control is difficult with monotherapy. Additionally, this medication is used as an alternative treatment when blood sugar control is insufficient with either metformin or sitagliptin monotherapy. If blood sugar control is still challenging with combination therapy of metformin and sulfonylureas, or metformin and thiazolidinediones, this medication can be added for enhanced efficacy. If blood sugar control remains difficult during combined therapy with insulin and metformin, this medication can also be co-administered to improve control. Overall, this medication is effectively used in conjunction with diet and exercise therapy to improve blood sugar control in type 2 diabetes.
The dose of this drug for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this drug 50/500 mg twice daily. The dose may be increased to 1 tablet of this drug 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Must Not Be Given This Drug). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Be Given This Drug).
This medication consists of two components, the first being a drug that helps control blood sugar levels and the second being another medication used to lower blood sugar. When taking this medication, severe allergic reactions may occur. If symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a physician. Pancreatitis may develop, hence if symptoms such as abdominal pain, nausea, or vomiting appear, discontinue use immediately and inform healthcare personnel. One component of this medication can rarely cause a serious condition called lactic acidosis, which involves excessive lactate buildup in the body. This condition may present with symptoms such as muscle pain, weakness, difficulty breathing, abdominal pain, and altered consciousness, so caution is advised. This medication should not be used in patients with severely impaired kidney function, severe infections, heart failure, or acute myocardial infarction. Discontinue use of this medication temporarily before surgeries or tests involving radiologic contrast agents, and resume only after confirming normal kidney function. Women who are pregnant or may become pregnant, and breastfeeding women, should not take this medication. During treatment, symptoms of hypoglycemia may occur due to blood sugar dropping too low, so it is particularly important to monitor blood sugar levels frequently and be alert for symptoms of hypoglycemia, especially when taken in conjunction with other hypoglycemic agents. This medication may affect liver and kidney functions, so regular blood tests and kidney function evaluations should be performed, and any atypical symptoms should prompt immediate consultation with medical staff. Alcohol consumption can be dangerous when taking this medication, so it is advisable to avoid drinking during the therapy. Maintaining healthy lifestyle practices, including regular meals and exercise, regular blood tests, and consultations with healthcare personnel, is essential while on this medication.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air, and keep it at room temperature between 1 to 30 degrees Celsius. This storage method will help maintain the medication's efficacy.
Pink oval film-coated tablets
56 tablets (14 tablets/PTP*4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hanol Bio Pharma Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.